CARDIOVASCULAR OUTCOMES IN DIABETIC PATIENTS TREATED WITH SGLT2i AND GLP1-RA: SYSTEMATIC REVIEW AND META-ANALYSIS
Anno:
2025
Background. SGLT2-i (sodium-glucose cotrasporter-2 inhibitor) and GLP1-RA (glucagon-like peptide receptor agonist) are two new classes of glucose-lowering drugs for the treatment of diabetes mellitus. Several important randomized clinical trials demonstrated a reduction in the risk of cardiovascular events in patients with type 2 diabetes mellitus treated with SGLT2-i and GLP1-RA….